For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globallyCombined in-licensing and financing for a novel long-acting clinical ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.

Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...